RecruitingPhase 3NCT05841056
Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial
Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients (START-POAF) Pilot Trial
Sponsor
Population Health Research Institute
Enrollment
400 participants
Start Date
Jun 13, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The START-POAF pilot study is a prospective, open-label two-arm, randomized controlled trial with blinded assessment of outcomes (PROBE). This pilot study will assess Atrial Fibrillation (AF) recurrence and burden in patients with new-onset AF following cardiac surgery.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Aged ≥18 years;
- Have undergone cardiac surgery including CABG, valve surgery, ascending aorta replacement, or combinations thereof within 14 days of randomization;
- Had new-onset POAF (or flutter), documented by 12-lead ECG or lasting ≥ 1 hour on telemetry. Patients can be in AF or sinus rhythm at the time of randomization;
- Expected to receive 3 g - 5 g of amiodarone loading dose post-surgery.
- Expected to be ready for hospital discharge within 48 h of randomization.
Exclusion Criteria6
- Documented preoperative history of paroxysmal, persistent or permanent AF;
- Planned use of a class I or III anti-arrhythmic drug (other than study drug);
- Patients who have undergone heart transplant, complex congenital heart surgery, isolated ventricular assist device insertion, or AF ablation (surgical or catheter);
- Known allergy to ECG adhesives;
- Contraindication to amiodarone (i.e. hyperthyroidism, severe restrictive or obstructive lung disease, Long QT syndrome, PR \> 240 ms, high-grade AV block).
- Individuals who are pregnant, breastfeeding, or of childbearing potential - female subjects, premenopausal who are not surgically sterile, or, if sexually active not practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and, for those of childbearing potential, who have a positive pregnancy test at screening
Interventions
DRUGAmiodarone Hydrochloride 200 MG
200 mg daily for 4 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05841056
Related Trials
BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction
NCT045285115 locations
Effect of Left Posterior Pericardiotomy for the Prevention of POAF
NCT061599851 location
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
NCT069493191 location
EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source
NCT067154491 location
Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
NCT060557512 locations